{
  "topic": "comprehensive KYC and credit risk analysis for Ion Beam Applications SA",
  "chapters": [
    {
      "chapter_title": "Risk Factors",
      "sections": [
        {
          "chapter_title": "Risk Factors",
          "section_title": "AML Issues",
          "description": "History of sanctions, money laundering, regulatory findings.",
          "questions": [
            {
              "question": "What are the historical sanctions imposed on entities and individuals related to Ion Beam Applications SA?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA sanctions history",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Entity sanctions related to Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Individuals sanctioned for dealings with Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the key findings of regulatory bodies and law enforcement agencies regarding money laundering and AML issues in the company's operations?",
              "queries": [
                {
                  "query": "Regulatory findings on money laundering by Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "AML issues in Ion Beam Applications SA business operations",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Law enforcement reports on financial crimes involving Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the specific AML and compliance deficiencies identified in previous assessments or audits of Ion Beam Applications SA?",
              "queries": [
                {
                  "query": "AML deficiencies in Ion Beam Applications SA risk assessments",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Compliance issues identified in Ion Beam Applications SA audit reports",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Previous AML and KYC related concerns about Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "Are there any notable cases or instances of money laundering, sanctions evasion, or other financial crimes linked to Ion Beam Applications SA?",
              "queries": [
                {
                  "query": "Money laundering cases involving Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Sanctions evasion schemes related to Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Financial crime cases linked to Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "chapter_title": "Risk Factors",
          "section_title": "Compliance Assessment",
          "description": "Adherence to regulatory standards.",
          "questions": [
            {
              "question": "What are the regulatory standards applicable to Ion Beam Applications SA for KYC and credit risk analysis?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA regulatory compliance",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "KYC and credit risk analysis regulations",
                  "results": [
                    {
                      "text": "gically, further authorizations may be \nrequired. Financial risks (sections 3:6, 1, 8 and 3:32, 1, 5, of the BCAC) \nMore details regarding section 3:6, 1, 8, and \n3:32, 1, 5 of the BCAC is provided, where \nappropriate, in \nthe \nsection \nFinancial \nInstruments of this annual report, see page 162. The Groups overall financial risk management \nprogram seeks to minimize potential adverse \neffects arising from the unpredictability of \nfinancial markets on the Groups financial \nperformance. To this effect, the Group uses \nderivative financial instruments to hedge certain \nrisk exposures.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "compliance standards for fintech companies",
                  "results": [
                    {
                      "text": "We have also verified, in accordance with the draft standard on the verification of the compliance of \nthe financial statements with the European Uniform Electronic Format (hereinafter ESEF), the \ncompliance of the ESEF format with the regulatory technical standards established by the European \nDelegate Regulation No. 2019/815 of 17 December 2018 (hereinafter: Delegated Regulation). The board of directors is responsible for the preparation, in accordance with ESEF requirements, of \nthe consolida",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "How does Ion Beam Applications SA ensure adherence to anti-money laundering (AML) and know-your-customer (KYC) policies?",
              "queries": [
                {
                  "query": "AML and KYC policies for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "2 American Society for Radiation Oncology. Model Policies. Proton beam therapy (PBT). May 2023. https://www.astro.org/ASTRO/media/ASTRO/Daily%20Prac\ntice/PDFs/ASTROPBTModelPolicy.pdf \n3 Aetna. Proton Beam, Neutron Beam, and Carbon Ion \nRadiotherapy. Clinical Policy Bulletins, Aetna, October 3rd, 2023, https://www.aetna.com/cpb/medical/data/200_299/0270.ht\nml \nand Young Adult cancer patients (aged 22 years \nto 39 years), as well as patients with genetic \ndisorders, esophageal cancer, and advanced or \nunresectable pelvic tumors2.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "compliance with AML and KYC regulations",
                  "results": [
                    {
                      "text": "This right may be subject to the compliance \nto \ncovenants \nincluded \nin \nthe \nloan \nagreement, but only the covenants effective \non or before the end of the reporting period \ncould impact the classification",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "risk-based approach to customer due diligence",
                  "results": [
                    {
                      "text": "a fully end to end solution, that may \nbe supported by further strategic acquisitions \nand a stronger presence in key geographical \nareas like India and China. Principal risks and uncertainties faced by the \ncompany (sections 3:6, 1, 1 to 3 and 3:32, 1, 1 to 3, of the BCAC)\nAPPROACH TO RISK MANAGEMENT\nThe Board of Directors, supported by the \nManagement Team, the Risk Management \nCommittee, and the Audit Committee, oversees \nand manages enterprise risk.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the key requirements for credit risk assessment in the context of Ion Beam Applications SA's business operations?",
              "queries": [
                {
                  "query": "credit risk assessment for fintech companies",
                  "results": [
                    {
                      "text": "ose \ncooperation with the Groups operating units. Credit risk \nThe Group has exposure to credit risk. In order \nto cover this risk, the Company policy for \nequipment contracts is to have confirmed letters \nof credit issued by its customers prior to \nshipment of the equipment, or to contract a \nspecific credit insurance from either the Belgian \nofficial export credit agency Credendo or private \ninsurers. Besides, the consolidated financial statements \npresents the financial assets and the financial \nliabilities of the Group by valuation method (fair \nvalue and carrying amount).",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "regulatory requirements for loan origination and servicing",
                  "results": [
                    {
                      "text": "This right may be subject to the compliance \nto \ncovenants \nincluded \nin \nthe \nloan \nagreement, but only the covenants effective \non or before the end of the reporting period \ncould impact the classification",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "compliance with Basel Accords",
                  "results": [
                    {
                      "text": "ties are subject to \ncertain financial covenants. Following the terms of the S.R.I.W. and S.F.P.I. bond agreements, the Group agreed to comply \nwith a financial covenant relating to the IBA SAs \nlevel of equity (determines based on the \nstatutory accounts published and established in \ncompliance with accounting principles applicable \nin Belgium), which was met as of December 31, 2023. The financial covenants applying to the \nsyndicated bank facilities consist in (a) a \nmaximum net leverage ratio",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "Are there any specific guidelines or regulations that govern data protection and privacy for Ion Beam Applications SA's customers?",
              "queries": [
                {
                  "query": "data protection and privacy regulations",
                  "results": [
                    {
                      "text": "Committee for Protection and Prevention at \nWork. Beyond mere compliance with the law, IBA \nconducts its business in accordance with the \nhighest standards of honesty and integrity. In addition to the Code of Business Conduct, IBAs Data Handling Policy explains how IBA \ncomplies with the General Data Protection \nRegulation (GDPR) to protect the Personal Data \nof \nclients, suppliers, patients, investors, contractors, staff members, and anyone else IBA \nis doing business with.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "GDPR compliance for fintech companies",
                  "results": [
                    {
                      "text": "Committee for Protection and Prevention at \nWork. Beyond mere compliance with the law, IBA \nconducts its business in accordance with the \nhighest standards of honesty and integrity. In addition to the Code of Business Conduct, IBAs Data Handling Policy explains how IBA \ncomplies with the General Data Protection \nRegulation (GDPR) to protect the Personal Data \nof \nclients, suppliers, patients, investors, contractors, staff members, and anyone else IBA \nis doing business with.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "customer data handling best practices",
                  "results": [
                    {
                      "text": "Committee for Protection and Prevention at \nWork. Beyond mere compliance with the law, IBA \nconducts its business in accordance with the \nhighest standards of honesty and integrity. In addition to the Code of Business Conduct, IBAs Data Handling Policy explains how IBA \ncomplies with the General Data Protection \nRegulation (GDPR) to protect the Personal Data \nof \nclients, suppliers, patients, investors, contractors, staff members, and anyone else IBA \nis doing business with.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "chapter_title": "Risk Factors",
          "section_title": "Financial Fraud",
          "description": "Known fraud incidents or allegations.",
          "questions": [
            {
              "question": "What are the known financial fraud incidents or allegations against Ion Beam Applications SA?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA financial fraud",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Ion Beam Applications SA scandals",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Ion Beam Applications SA controversies",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "How does the company's management address and respond to allegations of financial misconduct?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA corporate governance",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Ion Beam Applications SA whistleblower policies",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Ion Beam Applications SA compliance with regulatory bodies",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the consequences of any confirmed or alleged financial fraud on Ion Beam Applications SA's reputation, share price, and business operations?",
              "queries": [
                {
                  "query": "Impact of financial fraud on Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Financial fraud case studies in Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Reputation risk management in Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "Have there been any regulatory actions or investigations related to financial misconduct against Ion Beam Applications SA?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA regulatory enforcement",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Ion Beam Applications SA SEC filings",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Financial investigation results on Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    {
      "chapter_title": "Financials",
      "sections": [
        {
          "chapter_title": "Financials",
          "section_title": "Auditors' Report",
          "description": "Summary of external audit findings.",
          "questions": [
            {
              "question": "What are the key findings and recommendations from the auditors regarding KYC procedures in Ion Beam Applications SA?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA audit report KYC procedures",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "KYC process deficiencies Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Auditor's review of customer due diligence practices",
                  "results": [
                    {
                      "text": "and an update of a \nnumber of internal processes. This evaluation \nfocused on key risk areas such as corruption, asset misappropriation, financial statement \nfraud, cyberfraud of theft of data, and contract \nand procurement fraud. As a second phase, informal training of employees is taking place on \na daily basis. A system of formal reporting is also \ndescribed in the Code of Business Conduct and \nencourages the denunciation of such practices, amongst \nothers \nthrough \nthe \nanonimous \nwhistleblower platform on the Companys \nwebsite.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What credit risk analysis has been conducted by the auditors and what are the identified risks for Ion Beam Applications SA?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA credit risk assessment audit report",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Audit findings on loan and credit facilities management",
                  "results": [
                    {
                      "text": "lyzing \nadditional billing in case of variations. The Group's management relies on the knowledge of project \nmanagers, the granularity of its internal control system, and the experience gained from completed \nprojects. We considered this matter to be a key audit matter due to the significance of the balances in the \nfinancial statements and the level of judgment involved in important assumptions. How our Audit addressed the Key Audit Matter",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Risk analysis of customer default rates",
                  "results": [
                    {
                      "text": "he Dosimetry segment of -0.46% \n(-0.40% in 2022). Interest rate risk \nThe Groups exposure to changes in market \ninterest rates relates primarily to the Groups \nlong-term debt obligations with floating interest \nrates which were fully repaid in 2023. When the \nGroup considers that the fluctuation of interest \nrates could have a significant impact on its \nfinancial results, the Group will use interest rate \nswaps in order to mitigate this impact. IBA does not apply hedge accounting to these \ntransactions, and \nthese \ninstruments \nare \ntherefore revalued through profit and loss.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "Are there any material weaknesses or deficiencies in the internal controls over financial reporting at Ion Beam Applications SA?",
              "queries": [
                {
                  "query": "Internal control weaknesses audit report Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Material weaknesses in financial reporting process",
                  "results": [
                    {
                      "text": "es \nin \nthe \npreparation of their local accounts. Risk management process \nFinancial statements are consolidated monthly. This procedure enables the timely identification \nof accounting issues. The finance department works closely with the \nlegal department and external auditors, to \ncomply \nwith \nchanges \nin \nlegislation \nand \naccounting standards. These efforts are made to provide financial \ninformation in full compliance with company law, deadlines, and quality standards.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Audit findings on financial statement accuracy",
                  "results": [
                    {
                      "text": "tatements for the year ended December 31, 2023 are consistent with those followed in the \npreparation of the Groups annual consolidated \nfinancial statements for the year ended \nDecember 31, 2022, except for the adoption of \nnew standards and interpretations effective as \nof 1 January 2023. Changes in estimates are accounted for \nprospectively. Significant errors are accounted \nfor retrospectively, but there were no such \nsignificant accounting errors recorded in these \nconsolidated financial st",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the auditor's views on the adequacy of Ion Beam Applications SA's risk management framework and internal controls?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA risk management framework audit report",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Auditor's assessment of enterprise risk management practices",
                  "results": [
                    {
                      "text": "Committee, oversees \nand manages enterprise risk. The Management \nTeam, the Risk Management Committee, and \nthe Audit Committee identified several functional \nexperts covering the various categories of \nenterprise risk. The Management Team and the \nRisk Management Committee are continuously \nworking \nto \nimprove \nthe \nenterprise \nrisk \nmanagement framework and are responsible for \nthe \nimplementation \nof \nappropriate \nrisk \nresponses. Enterprise Risk Management focuses on five \nrisk categories: Strategic, Operational, Legal \nand Compliance, Digital, and Financial risks.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Internal control effectiveness review",
                  "results": [
                    {
                      "text": "d or not, and \ncommercial or financial in nature. Management \nEvaluation of the internal control system takes \nplace primarily when the management bodies \nreview the financial statements and analyses \nprepared by the Finance Department, as well as \nduring the follow-up on the effectiveness of \ninternal control and risk management systems \nby the Audit Committee. The analysis tools referred to above are \nestablished in line with the accounting principles \nvalidated by the Audit Committee and Boar",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "chapter_title": "Financials",
          "section_title": "Credit Rating & Financial Health",
          "description": "Credit ratings, solvency, liquidity ratios.",
          "questions": [
            {
              "question": "How does Ion Beam Applications SA's credit rating reflect its financial health and solvency?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA credit rating analysis",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "financial health assessment of Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "solvency ratios of Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the key liquidity ratios that indicate Ion Beam Applications SA's ability to meet its short-term obligations?",
              "queries": [
                {
                  "query": "liquidity ratio analysis of Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "short-term debt to equity ratio of Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "STATUTORY AUDITOR'S REPORT TO THE GENERAL SHAREHOLDERS MEETING OF ION \nBEAM APPLICATION SA ON THE CONSOLIDATED ACCOUNTS FOR THE YEAR ENDED \n31 DECEMBER 2023",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "current ratio calculation for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "Are there any industry benchmarks or peer comparisons that can be used to evaluate Ion Beam Applications SA's creditworthiness?",
              "queries": [
                {
                  "query": "creditworthiness benchmarking in the industrial equipment sector",
                  "results": [
                    {
                      "text": "ensive \nand demanding in its field, attests to IBA's \neffective commitment to objectives that are \naimed at both the collective interest and \nshareholder \nprofit. The \nperformance \nis \nparticularly remarkable for an international \nindustrial company of IBA's size. The B Corp certification process covered all of \nIBA's activities and assessed five main areas of \nimpact: governance, workers, community, environment and customers.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Ion Beam Applications SA credit rating compared to peers",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "industry average solvency ratios for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What specific risk factors or challenges might impact Ion Beam Applications SA's financial health and credit rating?",
              "queries": [
                {
                  "query": "credit risk assessment of Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "financial risks facing Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "industry-specific challenges affecting Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "chapter_title": "Financials",
          "section_title": "Financial Statements / Metrics",
          "description": "Income statements, balance sheets, key performance metrics.",
          "questions": [
            {
              "question": "What are the key financial metrics presented in Ion Beam Applications SA's income statements and balance sheets that indicate its revenue growth, profitability, and liquidity?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA income statement key performance indicators",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "balance sheet metrics for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "financial ratios for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "How does Ion Beam Applications SA's financial situation compare to its industry peers in terms of debt-to-equity ratio, return on equity, and asset turnover?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA financial performance compared to industry peers",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "debt-to-equity ratio analysis for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "return on equity calculation for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "STATUTORY AUDITOR'S REPORT TO THE GENERAL SHAREHOLDERS MEETING OF ION \nBEAM APPLICATION SA ON THE CONSOLIDATED ACCOUNTS FOR THE YEAR ENDED \n31 DECEMBER 2023",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the trends in Ion Beam Applications SA's key performance metrics, such as operating margin, net income margin, and cash flow margin, over a specified period?",
              "queries": [
                {
                  "query": "operating margin trend analysis for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "cash flow margin calculation for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "net income margin analysis for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "How does Ion Beam Applications SA's financial health and stability impact its creditworthiness, considering factors such as leverage, interest coverage, and cash flow generation?",
              "queries": [
                {
                  "query": "credit risk assessment for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "leverage ratio analysis for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "interest coverage calculation for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "chapter_title": "Financials",
          "section_title": "Share Price",
          "description": "Market valuation and stock performance (if publicly listed).",
          "questions": [
            {
              "question": "What is the current market valuation of Ion Beam Applications SA, and how does it compare to its peers in the industry?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA market capitalization",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Ion Beam Applications SA stock price comparison with industry peers",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Market value of Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the key drivers behind the fluctuations in Ion Beam Applications SA's share price over the past 12 months?",
              "queries": [
                {
                  "query": "Reasons for fluctuation in Ion Beam Applications SA stock price",
                  "results": [
                    {
                      "text": "ions \ndiffer greatly from one country to another. Operational risks \nSale risk \nIn general, IBAs customers are diversified \n(public and private sector) and located on \nseveral continents. Each year the Company \ndepends on multiple orders, particularly for its \nproton therapy systems that are implemented \nover several financial years. One additional \norder or one order less, or changes in an order \nthat were not anticipated at the beginning of the \nyear, are characteristics of this field of business \nthat can have a significant impact over several \naccounting periods.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Key factors affecting Ion Beam Applications SA share price",
                  "results": [
                    {
                      "text": "STATUTORY AUDITOR'S REPORT TO THE GENERAL SHAREHOLDERS MEETING OF ION \nBEAM APPLICATION SA ON THE CONSOLIDATED ACCOUNTS FOR THE YEAR ENDED \n31 DECEMBER 2023",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Stock performance analysis of Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What is the company's history with dividend payments, and what does this suggest about its financial health?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA dividend payment history",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Dividend payout ratio of Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Financial stability indicators for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "How has the company's share price performed during periods of economic uncertainty, such as recessions or market downturns?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA stock performance during economic downturns",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Share price resilience of Ion Beam Applications SA during recession",
                  "results": [
                    {
                      "text": "STATUTORY AUDITOR'S REPORT TO THE GENERAL SHAREHOLDERS MEETING OF ION \nBEAM APPLICATION SA ON THE CONSOLIDATED ACCOUNTS FOR THE YEAR ENDED \n31 DECEMBER 2023",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Company stock price stability analysis",
                  "results": [
                    {
                      "text": "The Company used the Black & Scholes model to value options, with no vesting conditions other than time. Expected \nvolatility for the stock option plans is based on historical volatility determined by statistical analysis of daily share price \nmovements. The exercise price of shares for the stock option plans was based on the average share price for the 30 days \npreceding the grant date. === Page 165 ===\nIBA Annual Report 2023 \n162. (EUR 000) \nFINANCIAL LIABILITIES \nDecember 31, 2022 \nDue \n< 1 y",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the most significant risks and challenges facing Ion Beam Applications SA's share price in the near future?",
              "queries": [
                {
                  "query": "Risks to Ion Beam Applications SA share price",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Challenges facing Ion Beam Applications SA stock performance",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Company stock price forecasting",
                  "results": [
                    {
                      "text": "The Company used the Black & Scholes model to value options, with no vesting conditions other than time. Expected \nvolatility for the stock option plans is based on historical volatility determined by statistical analysis of daily share price \nmovements. The exercise price of shares for the stock option plans was based on the average share price for the 30 days \npreceding the grant date. === Page 165 ===\nIBA Annual Report 2023 \n162. (EUR 000) \nFINANCIAL LIABILITIES \nDecember 31, 2022 \nDue \n< 1 y",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    {
      "chapter_title": "Introduction / Background",
      "sections": [
        {
          "chapter_title": "Introduction / Background",
          "section_title": "Company Overview",
          "description": "Basic company identification and registration details (name, incorporation date, registration number, legal form, jurisdiction, address, ownership structure).",
          "questions": [
            {
              "question": "What is the full legal name of Ion Beam Applications SA as per official records?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA company name",
                  "results": [
                    {
                      "text": "=== Page 185 ===\nIBA Annual Report 2021 \n182. CORPORATE NAME \nIon Beam Applications SA, abbreviated IBA SA. Following a resolution of the Extraordinary \nGeneral Meeting of shareholders of the \nCompany held on June 14, 2023 article 1 of the \nbylaws has been amended and now reads as \nfollows: Article 1: The Company takes the form of a public limited \ncompany. The name of the Company is Ion \nBeam Applications and, in short, IBA. \" \nREGISTERED OFFICE \nChemin du Cyclotron, 3; B-1348 Louvain-la-\nNeuve",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "official company name Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "=== Page 185 ===\nIBA Annual Report 2021 \n182. CORPORATE NAME \nIon Beam Applications SA, abbreviated IBA SA. Following a resolution of the Extraordinary \nGeneral Meeting of shareholders of the \nCompany held on June 14, 2023 article 1 of the \nbylaws has been amended and now reads as \nfollows: Article 1: The Company takes the form of a public limited \ncompany. The name of the Company is Ion \nBeam Applications and, in short, IBA. \" \nREGISTERED OFFICE \nChemin du Cyclotron, 3; B-1348 Louvain-la-\nNeuve",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "legal name Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "=== Page 185 ===\nIBA Annual Report 2021 \n182. CORPORATE NAME \nIon Beam Applications SA, abbreviated IBA SA. Following a resolution of the Extraordinary \nGeneral Meeting of shareholders of the \nCompany held on June 14, 2023 article 1 of the \nbylaws has been amended and now reads as \nfollows: Article 1: The Company takes the form of a public limited \ncompany. The name of the Company is Ion \nBeam Applications and, in short, IBA. \" \nREGISTERED OFFICE \nChemin du Cyclotron, 3; B-1348 Louvain-la-\nNeuve",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "On what date was Ion Beam Applications SA incorporated?",
              "queries": [
                {
                  "query": "inception date of Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "incorporation date Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "founding date Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "=== Page 185 ===\nIBA Annual Report 2021 \n182. CORPORATE NAME \nIon Beam Applications SA, abbreviated IBA SA. Following a resolution of the Extraordinary \nGeneral Meeting of shareholders of the \nCompany held on June 14, 2023 article 1 of the \nbylaws has been amended and now reads as \nfollows: Article 1: The Company takes the form of a public limited \ncompany. The name of the Company is Ion \nBeam Applications and, in short, IBA. \" \nREGISTERED OFFICE \nChemin du Cyclotron, 3; B-1348 Louvain-la-\nNeuve",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What is the registration number or ID assigned to Ion Beam Applications SA by its respective jurisdiction?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA registration number",
                  "results": [
                    {
                      "text": "=== Page 185 ===\nIBA Annual Report 2021 \n182. CORPORATE NAME \nIon Beam Applications SA, abbreviated IBA SA. Following a resolution of the Extraordinary \nGeneral Meeting of shareholders of the \nCompany held on June 14, 2023 article 1 of the \nbylaws has been amended and now reads as \nfollows: Article 1: The Company takes the form of a public limited \ncompany. The name of the Company is Ion \nBeam Applications and, in short, IBA. \" \nREGISTERED OFFICE \nChemin du Cyclotron, 3; B-1348 Louvain-la-\nNeuve",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "company ID Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "official registry number Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "=== Page 185 ===\nIBA Annual Report 2021 \n182. CORPORATE NAME \nIon Beam Applications SA, abbreviated IBA SA. Following a resolution of the Extraordinary \nGeneral Meeting of shareholders of the \nCompany held on June 14, 2023 article 1 of the \nbylaws has been amended and now reads as \nfollows: Article 1: The Company takes the form of a public limited \ncompany. The name of the Company is Ion \nBeam Applications and, in short, IBA. \" \nREGISTERED OFFICE \nChemin du Cyclotron, 3; B-1348 Louvain-la-\nNeuve",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    {
      "chapter_title": "Conclusion",
      "sections": [
        {
          "chapter_title": "Conclusion",
          "section_title": "Conclusion",
          "description": "Summary of risk profile and key takeaways.",
          "questions": [
            {
              "question": "What is the comprehensive risk profile of Ion Beam Applications SA, highlighting key credit and KYC risks?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA risk profile",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "KYC and credit risk analysis report",
                  "results": [
                    {
                      "text": "gically, further authorizations may be \nrequired. Financial risks (sections 3:6, 1, 8 and 3:32, 1, 5, of the BCAC) \nMore details regarding section 3:6, 1, 8, and \n3:32, 1, 5 of the BCAC is provided, where \nappropriate, in \nthe \nsection \nFinancial \nInstruments of this annual report, see page 162. The Groups overall financial risk management \nprogram seeks to minimize potential adverse \neffects arising from the unpredictability of \nfinancial markets on the Groups financial \nperformance. To this effect, the Group uses \nderivative financial instruments to hedge certain \nrisk exposures.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Comprehensive risk assessment IBA SA",
                  "results": [
                    {
                      "text": "anys risk management in the relevant risk \nareas. IBA \nhas \ndesigned \nits \nEnterprise \nRisk \nManagement based on the ERM Integrated \nframework (2017) established by the Committee \nof Sponsoring Organizations of the Treadway \nCommission (COSO). IBA \nis \ncontinuously \nimproving \nits \nrisk \nmanagement process and regularly assesses \nchanges that could affect its strategy and \nobjectives, including strategic, financial, human \nand environmental. Our quality management \nsystem is ISO9001, ISO13485, MDD and \nMDSAP certified. We are audited once a year by \nour Notified Body.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the main takeaways from the comprehensive KYC and credit risk analysis for Ion Beam Applications SA?",
              "queries": [
                {
                  "query": "Key findings KYC and credit risk analysis IBA SA",
                  "results": [
                    {
                      "text": "=== Page 164 ===\nIBA Annual Report 2023 \n161. 7. Description of financial risk management \n(sections 3:6, 1, 8 and 3:32, 1, 5, of the \nBCAC) \n7.1. DESCRIPTION OF FINANCIAL RISKS \nThe Group has decided to present its financial \nrisks with the other principal identified risks in \nthe section Principal risks and uncertainties \nfaced by the company starting on page 51. These include credit risk, foreign currency risk, interest rate risk, liquidity risk, covenant risks. 7.2.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Main conclusions comprehensive risk report",
                  "results": [
                    {
                      "text": "al \nand Compliance, Digital, and Financial risks. The main risks within these categories are \nfurther described. === Page 55 ===\nIBA Annual Report 2023 \n52. IBA \nIBA RISK MANAGEMENT FRAMEWORK\nRisk management is a core component of the \nIBA strategy and performance management \nprocess. The Board of Directors considers risk \nappetite when making decisions. The design and effectiveness of IBAs risk \nmanagement, practices, and \nthe \nrecommendations from internal and external \naudits are reported and discussed periodically \nwith the Risk Management Committee.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "IBA SA risk management recommendations",
                  "results": [
                    {
                      "text": "anys risk management in the relevant risk \nareas. IBA \nhas \ndesigned \nits \nEnterprise \nRisk \nManagement based on the ERM Integrated \nframework (2017) established by the Committee \nof Sponsoring Organizations of the Treadway \nCommission (COSO). IBA \nis \ncontinuously \nimproving \nits \nrisk \nmanagement process and regularly assesses \nchanges that could affect its strategy and \nobjectives, including strategic, financial, human \nand environmental. Our quality management \nsystem is ISO9001, ISO13485, MDD and \nMDSAP certified. We are audited once a year by \nour Notified Body.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "How does the comprehensive KYC and credit risk analysis for Ion Beam Applications SA support informed business decision-making?",
              "queries": [
                {
                  "query": "Business impact KYC and credit risk analysis IBA SA",
                  "results": [
                    {
                      "text": "anys risk management in the relevant risk \nareas. IBA \nhas \ndesigned \nits \nEnterprise \nRisk \nManagement based on the ERM Integrated \nframework (2017) established by the Committee \nof Sponsoring Organizations of the Treadway \nCommission (COSO). IBA \nis \ncontinuously \nimproving \nits \nrisk \nmanagement process and regularly assesses \nchanges that could affect its strategy and \nobjectives, including strategic, financial, human \nand environmental. Our quality management \nsystem is ISO9001, ISO13485, MDD and \nMDSAP certified. We are audited once a year by \nour Notified Body.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Decision-making support comprehensive risk report",
                  "results": [
                    {
                      "text": "al \nand Compliance, Digital, and Financial risks. The main risks within these categories are \nfurther described. === Page 55 ===\nIBA Annual Report 2023 \n52. IBA \nIBA RISK MANAGEMENT FRAMEWORK\nRisk management is a core component of the \nIBA strategy and performance management \nprocess. The Board of Directors considers risk \nappetite when making decisions. The design and effectiveness of IBAs risk \nmanagement, practices, and \nthe \nrecommendations from internal and external \naudits are reported and discussed periodically \nwith the Risk Management Committee.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "IBA SA risk-based management framework",
                  "results": [
                    {
                      "text": "anys risk management in the relevant risk \nareas. IBA \nhas \ndesigned \nits \nEnterprise \nRisk \nManagement based on the ERM Integrated \nframework (2017) established by the Committee \nof Sponsoring Organizations of the Treadway \nCommission (COSO). IBA \nis \ncontinuously \nimproving \nits \nrisk \nmanagement process and regularly assesses \nchanges that could affect its strategy and \nobjectives, including strategic, financial, human \nand environmental. Our quality management \nsystem is ISO9001, ISO13485, MDD and \nMDSAP certified. We are audited once a year by \nour Notified Body.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What specific steps can be taken to mitigate identified risks and improve the overall risk profile of Ion Beam Applications SA?",
              "queries": [
                {
                  "query": "Risk mitigation strategies IBA SA",
                  "results": [
                    {
                      "text": "anys risk management in the relevant risk \nareas. IBA \nhas \ndesigned \nits \nEnterprise \nRisk \nManagement based on the ERM Integrated \nframework (2017) established by the Committee \nof Sponsoring Organizations of the Treadway \nCommission (COSO). IBA \nis \ncontinuously \nimproving \nits \nrisk \nmanagement process and regularly assesses \nchanges that could affect its strategy and \nobjectives, including strategic, financial, human \nand environmental. Our quality management \nsystem is ISO9001, ISO13485, MDD and \nMDSAP certified. We are audited once a year by \nour Notified Body.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Comprehensive risk management plan IBA SA",
                  "results": [
                    {
                      "text": "anys risk management in the relevant risk \nareas. IBA \nhas \ndesigned \nits \nEnterprise \nRisk \nManagement based on the ERM Integrated \nframework (2017) established by the Committee \nof Sponsoring Organizations of the Treadway \nCommission (COSO). IBA \nis \ncontinuously \nimproving \nits \nrisk \nmanagement process and regularly assesses \nchanges that could affect its strategy and \nobjectives, including strategic, financial, human \nand environmental. Our quality management \nsystem is ISO9001, ISO13485, MDD and \nMDSAP certified. We are audited once a year by \nour Notified Body.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "IBA SA risk reduction initiatives",
                  "results": [
                    {
                      "text": "anys risk management in the relevant risk \nareas. IBA \nhas \ndesigned \nits \nEnterprise \nRisk \nManagement based on the ERM Integrated \nframework (2017) established by the Committee \nof Sponsoring Organizations of the Treadway \nCommission (COSO). IBA \nis \ncontinuously \nimproving \nits \nrisk \nmanagement process and regularly assesses \nchanges that could affect its strategy and \nobjectives, including strategic, financial, human \nand environmental. Our quality management \nsystem is ISO9001, ISO13485, MDD and \nMDSAP certified. We are audited once a year by \nour Notified Body.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    {
      "chapter_title": "Corporate Structure / Group Chart",
      "sections": [
        {
          "chapter_title": "Corporate Structure / Group Chart",
          "section_title": "Corporate Structure / Group Chart",
          "description": "Ownership structure, subsidiaries, ultimate beneficial owners (UBOs), holding companies, and group entities.",
          "questions": [
            {
              "question": "What is the ownership structure of Ion Beam Applications SA, including parent companies and subsidiaries?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA ownership structure",
                  "results": [
                    {
                      "text": "=== Page 185 ===\nIBA Annual Report 2021 \n182. CORPORATE NAME \nIon Beam Applications SA, abbreviated IBA SA. Following a resolution of the Extraordinary \nGeneral Meeting of shareholders of the \nCompany held on June 14, 2023 article 1 of the \nbylaws has been amended and now reads as \nfollows: Article 1: The Company takes the form of a public limited \ncompany. The name of the Company is Ion \nBeam Applications and, in short, IBA. \" \nREGISTERED OFFICE \nChemin du Cyclotron, 3; B-1348 Louvain-la-\nNeuve",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "parent companies Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "subdivisions Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "Who are the ultimate beneficial owners (UBOs) behind Ion Beam Applications SA and their respective roles within the company?",
              "queries": [
                {
                  "query": "ultimate beneficial owners Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Ion Beam Applications SA UBOs",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "key individuals involved in Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What is the corporate hierarchy, including holding companies and group entities, of Ion Beam Applications SA?",
              "queries": [
                {
                  "query": "corporate hierarchy Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "=== Page 185 ===\nIBA Annual Report 2021 \n182. CORPORATE NAME \nIon Beam Applications SA, abbreviated IBA SA. Following a resolution of the Extraordinary \nGeneral Meeting of shareholders of the \nCompany held on June 14, 2023 article 1 of the \nbylaws has been amended and now reads as \nfollows: Article 1: The Company takes the form of a public limited \ncompany. The name of the Company is Ion \nBeam Applications and, in short, IBA. \" \nREGISTERED OFFICE \nChemin du Cyclotron, 3; B-1348 Louvain-la-\nNeuve",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "holding companies related to Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "group entities connected to Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "Are there any known connections or affiliations between Ion Beam Applications SA and other organizations, individuals, or government agencies?",
              "queries": [
                {
                  "query": "affiliations Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "known connections Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "linked entities with Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    {
      "chapter_title": "ESG (Environmental, Social, Governance)",
      "sections": [
        {
          "chapter_title": "ESG (Environmental, Social, Governance)",
          "section_title": "ESG Targets",
          "description": "Companyâ€™s measurable ESG goals.",
          "questions": [
            {
              "question": "What are the Ion Beam Applications SA's ESG targets for climate change mitigation and adaptation?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA ESG targets climate change",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "ESG goals Ion Beam Applications SA sustainability",
                  "results": [
                    {
                      "text": "tions and help \nmake advancements in this field.. By leveraging high-powered ionizing technology, IBA is also actively investing in tangible solutions for \nenvironmental remediation, supported by ongoing \nexperiments yielding promising initial results and plans \nfor larger-scale demonstrations. IBA demonstrates that \nE-beam can be used for cleaner soils, air and water. A NEW EXPERIENCE, A JOURNEY TOGETHER, A RELATIONSHIP FOR LIFE: BEYONDTM\nInitially focused on the development of performant elect",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Carbon footprint reduction strategies Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the company's measurable ESG goals related to water conservation and resource management?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA ESG targets water conservation",
                  "results": [
                    {
                      "text": "tions and help \nmake advancements in this field.. By leveraging high-powered ionizing technology, IBA is also actively investing in tangible solutions for \nenvironmental remediation, supported by ongoing \nexperiments yielding promising initial results and plans \nfor larger-scale demonstrations. IBA demonstrates that \nE-beam can be used for cleaner soils, air and water. A NEW EXPERIENCE, A JOURNEY TOGETHER, A RELATIONSHIP FOR LIFE: BEYONDTM\nInitially focused on the development of performant elect",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "ESG goals Ion Beam Applications SA resource efficiency",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Water usage reduction strategies Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "ur water withdrawal intensity by 35% below 2020 levels by 2025. 306-2 Management of significant waste related impacts \nSubstituting inputs that have hazardous characteristics with inputs that are non-hazardous: IBA Industrial Solutions has developed a new portfolio of services and end-to-end solutions powered by the Rhodotron particle accelerator. These \ninnovative electrical solutions allow in-house customers or contract sterilizers to sterilize medical devices either by E-beam in boxes or X-ray in \npallets, or both.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What specific actions has the company taken or plans to take to address biodiversity loss and ecosystem degradation?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA ESG targets biodiversity conservation",
                  "results": [
                    {
                      "text": "ered is part of a more \neco-responsible approach. Coupled with the latest technologies in terms of green energy \nproduction, increased efficiency of the ionization process, recovery of fatal calories, co-generation, numerical modelling, digitalization, and product handling developed for the logistics \nindustry, irradiation can be further optimized to reduce the total \necological footprint of the sterilization industry compared to \nother established technologies.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "ESG goals Ion Beam Applications SA environmental stewardship",
                  "results": [
                    {
                      "text": "tions and help \nmake advancements in this field.. By leveraging high-powered ionizing technology, IBA is also actively investing in tangible solutions for \nenvironmental remediation, supported by ongoing \nexperiments yielding promising initial results and plans \nfor larger-scale demonstrations. IBA demonstrates that \nE-beam can be used for cleaner soils, air and water. A NEW EXPERIENCE, A JOURNEY TOGETHER, A RELATIONSHIP FOR LIFE: BEYONDTM\nInitially focused on the development of performant elect",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Biodiversity preservation strategies Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the company's measurable ESG goals related to social responsibility, including employee welfare and community engagement?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA ESG targets social responsibility",
                  "results": [
                    {
                      "text": "ered is part of a more \neco-responsible approach. Coupled with the latest technologies in terms of green energy \nproduction, increased efficiency of the ionization process, recovery of fatal calories, co-generation, numerical modelling, digitalization, and product handling developed for the logistics \nindustry, irradiation can be further optimized to reduce the total \necological footprint of the sterilization industry compared to \nother established technologies.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "ESG goals Ion Beam Applications SA human rights",
                  "results": [
                    {
                      "text": "amining \ntransactions with governments or government \ninstitutions and representatives, (iii) creating \nnew legal entities overseas with due diligence, and \n(iv) \neducating \nemployees \nthrough \ncommunications and proper training. Protection and Respect of Human \nRights \nPolicy and Targets \nThe Universal Declaration of Human Rights \ndefines human rights as rights inherent to all \nhuman \nbeings, regardless \nof \nrace, sex, nationality, ethnicity, language, religion, or any \nother status.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Community development initiatives Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What specific reporting frameworks or standards (e.g. GRI, SASB) does the company use to report its ESG progress and performance?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA ESG reporting framework",
                  "results": [
                    {
                      "text": "ESEF requirements under the Delegated Regulation. Based on our procedures performed, we believe that the format of and marking of information in the \ndigital consolidated financial statements included in the annual financial report of Ion Beam Application \nper 31 December 2023 comply in all material respects with the ESEF requirements under the \nDelegated Regulation. Other statements",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "ESG disclosure standards Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "ESEF requirements under the Delegated Regulation. Based on our procedures performed, we believe that the format of and marking of information in the \ndigital consolidated financial statements included in the annual financial report of Ion Beam Application \nper 31 December 2023 comply in all material respects with the ESEF requirements under the \nDelegated Regulation. Other statements",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Sustainability reporting guidelines Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "chapter_title": "ESG (Environmental, Social, Governance)",
          "section_title": "External ESG Ratings",
          "description": "Third-party ratings (e.g., MSCI, Sustainalytics).",
          "questions": [
            {
              "question": "What external ESG rating providers are commonly used for company evaluations?",
              "queries": [
                {
                  "query": "common ESG rating providers",
                  "results": [
                    {
                      "text": "pt-Ins are linked to said B Corp score \nincrease. We have selected Ecovadis as our \nservice \nprovider \nfor \nSupply \nChain \nESG \nscreening. And we closely survey the applicable \nand \nforthcoming \nnon-financial \nreporting \nregulations (GRI 2021, taxonomy, CSRD, due \ndiligence). THE \nNEW \nAND \nFORTHCOMING \nEU \nSUSTAINABLE FINANCE LANDSCAPE",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "ESG ratings MSCI Sustainalytics",
                  "results": [
                    {
                      "text": "pt-Ins are linked to said B Corp score \nincrease. We have selected Ecovadis as our \nservice \nprovider \nfor \nSupply \nChain \nESG \nscreening. And we closely survey the applicable \nand \nforthcoming \nnon-financial \nreporting \nregulations (GRI 2021, taxonomy, CSRD, due \ndiligence). THE \nNEW \nAND \nFORTHCOMING \nEU \nSUSTAINABLE FINANCE LANDSCAPE",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "company evaluation external ratings",
                  "results": [
                    {
                      "text": "d or not, and \ncommercial or financial in nature. Management \nEvaluation of the internal control system takes \nplace primarily when the management bodies \nreview the financial statements and analyses \nprepared by the Finance Department, as well as \nduring the follow-up on the effectiveness of \ninternal control and risk management systems \nby the Audit Committee. The analysis tools referred to above are \nestablished in line with the accounting principles \nvalidated by the Audit Committee and Boar",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "How do external ESG ratings impact investment decisions and risk assessment?",
              "queries": [
                {
                  "query": "impact of ESG ratings on investment decisions",
                  "results": [
                    {
                      "text": "pt-Ins are linked to said B Corp score \nincrease. We have selected Ecovadis as our \nservice \nprovider \nfor \nSupply \nChain \nESG \nscreening. And we closely survey the applicable \nand \nforthcoming \nnon-financial \nreporting \nregulations (GRI 2021, taxonomy, CSRD, due \ndiligence). THE \nNEW \nAND \nFORTHCOMING \nEU \nSUSTAINABLE FINANCE LANDSCAPE",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "ESG ratings in credit risk analysis",
                  "results": [
                    {
                      "text": "pt-Ins are linked to said B Corp score \nincrease. We have selected Ecovadis as our \nservice \nprovider \nfor \nSupply \nChain \nESG \nscreening. And we closely survey the applicable \nand \nforthcoming \nnon-financial \nreporting \nregulations (GRI 2021, taxonomy, CSRD, due \ndiligence). THE \nNEW \nAND \nFORTHCOMING \nEU \nSUSTAINABLE FINANCE LANDSCAPE",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "external ratings influence investor behavior",
                  "results": [
                    {
                      "text": "d or not, and \ncommercial or financial in nature. Management \nEvaluation of the internal control system takes \nplace primarily when the management bodies \nreview the financial statements and analyses \nprepared by the Finance Department, as well as \nduring the follow-up on the effectiveness of \ninternal control and risk management systems \nby the Audit Committee. The analysis tools referred to above are \nestablished in line with the accounting principles \nvalidated by the Audit Committee and Boar",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "Can external ESG ratings be used as an indicator for company sustainability and social responsibility?",
              "queries": [
                {
                  "query": "relationship between ESG ratings and corporate social responsibility",
                  "results": [
                    {
                      "text": "pt-Ins are linked to said B Corp score \nincrease. We have selected Ecovadis as our \nservice \nprovider \nfor \nSupply \nChain \nESG \nscreening. And we closely survey the applicable \nand \nforthcoming \nnon-financial \nreporting \nregulations (GRI 2021, taxonomy, CSRD, due \ndiligence). THE \nNEW \nAND \nFORTHCOMING \nEU \nSUSTAINABLE FINANCE LANDSCAPE",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "using ESG ratings to measure sustainability performance",
                  "results": [
                    {
                      "text": "pt-Ins are linked to said B Corp score \nincrease. We have selected Ecovadis as our \nservice \nprovider \nfor \nSupply \nChain \nESG \nscreening. And we closely survey the applicable \nand \nforthcoming \nnon-financial \nreporting \nregulations (GRI 2021, taxonomy, CSRD, due \ndiligence). THE \nNEW \nAND \nFORTHCOMING \nEU \nSUSTAINABLE FINANCE LANDSCAPE",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "ESG ratings as a proxy for corporate governance",
                  "results": [
                    {
                      "text": "pt-Ins are linked to said B Corp score \nincrease. We have selected Ecovadis as our \nservice \nprovider \nfor \nSupply \nChain \nESG \nscreening. And we closely survey the applicable \nand \nforthcoming \nnon-financial \nreporting \nregulations (GRI 2021, taxonomy, CSRD, due \ndiligence). THE \nNEW \nAND \nFORTHCOMING \nEU \nSUSTAINABLE FINANCE LANDSCAPE",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What is the methodology used by external ESG rating providers to evaluate companies?",
              "queries": [
                {
                  "query": "methodology behind ESG rating calculations",
                  "results": [
                    {
                      "text": "pt-Ins are linked to said B Corp score \nincrease. We have selected Ecovadis as our \nservice \nprovider \nfor \nSupply \nChain \nESG \nscreening. And we closely survey the applicable \nand \nforthcoming \nnon-financial \nreporting \nregulations (GRI 2021, taxonomy, CSRD, due \ndiligence). THE \nNEW \nAND \nFORTHCOMING \nEU \nSUSTAINABLE FINANCE LANDSCAPE",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "how do MSCI and Sustainalytics evaluate companies",
                  "results": [
                    {
                      "text": "d or not, and \ncommercial or financial in nature. Management \nEvaluation of the internal control system takes \nplace primarily when the management bodies \nreview the financial statements and analyses \nprepared by the Finance Department, as well as \nduring the follow-up on the effectiveness of \ninternal control and risk management systems \nby the Audit Committee. The analysis tools referred to above are \nestablished in line with the accounting principles \nvalidated by the Audit Committee and Boar",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "ESG rating criteria for company evaluation",
                  "results": [
                    {
                      "text": "pt-Ins are linked to said B Corp score \nincrease. We have selected Ecovadis as our \nservice \nprovider \nfor \nSupply \nChain \nESG \nscreening. And we closely survey the applicable \nand \nforthcoming \nnon-financial \nreporting \nregulations (GRI 2021, taxonomy, CSRD, due \ndiligence). THE \nNEW \nAND \nFORTHCOMING \nEU \nSUSTAINABLE FINANCE LANDSCAPE",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    {
      "chapter_title": "Business Activities",
      "sections": [
        {
          "chapter_title": "Business Activities",
          "section_title": "Geographical Market & Coverage",
          "description": "Key regions of operation and geographical exposure.",
          "questions": [
            {
              "question": "What are the primary geographic markets for Ion Beam Applications SA's products or services?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA market regions",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "geographic coverage of Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "primary markets for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "How does Ion Beam Applications SA's geographical presence impact its credit risk and KYC requirements?",
              "queries": [
                {
                  "query": "credit risk and KYC implications of Ion Beam Applications SA's geography",
                  "results": [
                    {
                      "text": "2022), and unused overdraft \nfacilities in China. Credit facilities \nIBA SA has access to EUR 44.5 million (initially, EUR 67 million) syndicated credit facilities in the \nform of EUR 40 million revolving credit facilities \nmaturing in December 2024. The revolving \ncredit facilities remained undrawn as of \nDecember 31, 2023. In China, the CNY 35 million overdraft facility \n(borrower: Ion Beam Applications Co. Ltd) was \nmaintained for the same amount (undrawn). Covenant risk \nThe above-mentionned facilities are subject to \ncertain financial covenants.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "geographical exposure of Ion Beam Applications SA for credit risk",
                  "results": [
                    {
                      "text": "2022), and unused overdraft \nfacilities in China. Credit facilities \nIBA SA has access to EUR 44.5 million (initially, EUR 67 million) syndicated credit facilities in the \nform of EUR 40 million revolving credit facilities \nmaturing in December 2024. The revolving \ncredit facilities remained undrawn as of \nDecember 31, 2023. In China, the CNY 35 million overdraft facility \n(borrower: Ion Beam Applications Co. Ltd) was \nmaintained for the same amount (undrawn). Covenant risk \nThe above-mentionned facilities are subject to \ncertain financial covenants.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "KYC considerations for Ion Beam Applications SA's global operations",
                  "results": [
                    {
                      "text": "=== Page 199 ===\niba-worldwide.com\nContact IBA\nCorporate Communication\nTel. +32 10 47 58 90\nE-mail: communiation@iba-group.com\nIon Beam Applications, SA\nChemin du Cyclotron, 3\n1348 Louvain-la-Neuve, Belgium\nTel. +32 10 47 58 11 - Fax: +32 10 47 58 10\nRPM Nivelles - TVA: BE 428.750.985\nE-mail: info-worldwide@iba-group.com\nwww.iba-worldwide.com\nE.R. IBA SA, chemin du Cyclotron, 3\n1348 Louvain-la-Neuve, Belgium\nDesign & Production: www.thecrew.be",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the key regional differences in demand, competition, or regulatory environments that affect Ion Beam Applications SA?",
              "queries": [
                {
                  "query": "regional differences in demand and competition for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "=== Page 17 ===\nAN EVEN FASTER GROWTH \nIN AMERICA AND ASIA\nUntil recently, reference sites for X-ray and electron beam \nindustrial sterilization were mostly concentrated in central \nEurope. Today, IBA Industrial sees a strong deployment of the \ntechnology in all regions of the world, with remarkable activity \nin the United States, Southeast Asia and China. IBA is currently \ndeploying a stronger regionalization plan in those areas where it \nis already present, including adding resources for installations \nand services, hubs for parts logistics, and third-party suppliers.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "geographic variations in regulations affecting Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "ions \ndiffer greatly from one country to another. Operational risks \nSale risk \nIn general, IBAs customers are diversified \n(public and private sector) and located on \nseveral continents. Each year the Company \ndepends on multiple orders, particularly for its \nproton therapy systems that are implemented \nover several financial years. One additional \norder or one order less, or changes in an order \nthat were not anticipated at the beginning of the \nyear, are characteristics of this field of business \nthat can have a significant impact over several \naccounting periods.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "impact of regional markets on Ion Beam Applications SA's credit risk",
                  "results": [
                    {
                      "text": "ions \ndiffer greatly from one country to another. Operational risks \nSale risk \nIn general, IBAs customers are diversified \n(public and private sector) and located on \nseveral continents. Each year the Company \ndepends on multiple orders, particularly for its \nproton therapy systems that are implemented \nover several financial years. One additional \norder or one order less, or changes in an order \nthat were not anticipated at the beginning of the \nyear, are characteristics of this field of business \nthat can have a significant impact over several \naccounting periods.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "chapter_title": "Business Activities",
          "section_title": "Industry",
          "description": "Sector classification and position within the industry.",
          "questions": [
            {
              "question": "How does Ion Beam Applications SA's position in the industry affect its risk profile?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA industry classification",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "company position in ion beam technology industry",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "industry risk profile factors for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the key sectoral trends that impact Ion Beam Applications SA's creditworthiness?",
              "queries": [
                {
                  "query": "sectoral trends affecting ion beam applications sa credit",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "creditworthiness factors in high-tech manufacturing industry",
                  "results": [
                    {
                      "text": "ose \ncooperation with the Groups operating units. Credit risk \nThe Group has exposure to credit risk. In order \nto cover this risk, the Company policy for \nequipment contracts is to have confirmed letters \nof credit issued by its customers prior to \nshipment of the equipment, or to contract a \nspecific credit insurance from either the Belgian \nofficial export credit agency Credendo or private \ninsurers. Besides, the consolidated financial statements \npresents the financial assets and the financial \nliabilities of the Group by valuation method (fair \nvalue and carrying amount).",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "key drivers of financial performance for ion beam companies",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "How does Ion Beam Applications SA's business model influence its risk exposure?",
              "queries": [
                {
                  "query": "ion beam applications sa business model analysis",
                  "results": [
                    {
                      "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "risk exposure factors in ion beam technology business",
                  "results": [
                    {
                      "text": "assessing \nperformance of the operating segments. On the basis of its internal financial reports and given the Groups primary source \nof risk and profitability, IBA has identified two operating segments: - \nProton therapy and other accelerators: This segment constitutes the technological basis of the Groups many \nbusinesses and encompasses development, fabrication, and services associated with medical and industrial \nparticle accelerators and proton therapy systems. - \nDosimetry: This segment in",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "business model innovation and creditworthiness in high-tech industry",
                  "results": [
                    {
                      "text": "nificant impact over several \naccounting periods. On the other hand, the lead \ntime for fulfilling orders gives the Company a \ngood view of its level of activity several months \nin advance. Inventory risk \nInventory includes high technology parts and \ncomponents subject to rapid technological \nobsolescence. Inventory support production but \nalso spare parts to support our customers. IBA \noptimizes the level of inventory required for \nproduction and support on sites for our \ncustomers under a maintenance contract.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the regulatory requirements for Ion Beam Applications SA's sector, and how might they impact its risk profile?",
              "queries": [
                {
                  "query": "regulatory requirements for ion beam applications sa",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "industry regulations affecting credit risk for ion beam companies",
                  "results": [
                    {
                      "text": "ESEF requirements under the Delegated Regulation. Based on our procedures performed, we believe that the format of and marking of information in the \ndigital consolidated financial statements included in the annual financial report of Ion Beam Application \nper 31 December 2023 comply in all material respects with the ESEF requirements under the \nDelegated Regulation. Other statements",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "compliance risks in high-tech manufacturing industry",
                  "results": [
                    {
                      "text": "uests close interactions with all those \nvendors. Quality risk / consumer protection / \nproduct safety risk \nIBA is required to comply with quality standards \nin the manufacture of its medical devices and is \nsubject to the supervision of various national \nauthorities. Conditions imposed by such national \nregulatory authorities could result in product \nrecalls or a temporary ban on products. This \ncould have an impact on IBAs reputation, customer satisfaction, and could lead to financial \nlosses. Errors or accidents could arise from the \noperation of our products.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "chapter_title": "Business Activities",
          "section_title": "Market Share",
          "description": "Relative position vs competitors, competitive advantages.",
          "questions": [
            {
              "question": "What is the market share of Ion Beam Applications SA compared to its competitors in the KYC and credit risk analysis industry?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA market share vs competitors",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "KYC and credit risk analysis industry market share by company",
                  "results": [
                    {
                      "text": "luation method (fair \nvalue and carrying amount). The carrying \namount of these financial assets represents the \nmaximum credit exposure of the Group. Foreign currency risk \nThe Group operates internationally and as such, is exposed to foreign exchange risks arising from \ncommercial transactions (sales and supply \ncontracts), from financial assets and liabilities, and from net investments in non-Eurozone \noperations.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Ion Beam Applications SA competitor analysis",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the competitive advantages of Ion Beam Applications SA in the KYC and credit risk analysis sector?",
              "queries": [
                {
                  "query": "competitive advantages Ion Beam Applications SA KYC and credit risk analysis",
                  "results": [
                    {
                      "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "market share drivers for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Ion Beam Applications SA unique selling points",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "How does Ion Beam Applications SA's market position compare to its peers in terms of innovation, product offerings, and service delivery?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA market positioning vs competitors",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "innovation leaders in KYC and credit risk analysis industry",
                  "results": [
                    {
                      "text": "a fully end to end solution, that may \nbe supported by further strategic acquisitions \nand a stronger presence in key geographical \nareas like India and China. Principal risks and uncertainties faced by the \ncompany (sections 3:6, 1, 1 to 3 and 3:32, 1, 1 to 3, of the BCAC)\nAPPROACH TO RISK MANAGEMENT\nThe Board of Directors, supported by the \nManagement Team, the Risk Management \nCommittee, and the Audit Committee, oversees \nand manages enterprise risk.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "product and service delivery comparison Ion Beam Applications SA vs competitors",
                  "results": [
                    {
                      "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the key factors influencing Ion Beam Applications SA's market share growth or decline in the KYC and credit risk analysis sector?",
              "queries": [
                {
                  "query": "drivers of market share growth for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "factors affecting market share decline Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "market trends impacting Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "requiring IBA to adapt to the evolving landscape. Nevertheless, the market continues to expand \non the long term, and this situation has neither \nreduced nor slowed down the interest in E-beam \nand X-ray solutions, but rather prompted IBA \nto further develop and enhance its products offerings \nand customer service. To capture this long-term trend, IBA has developed \na new portfolio of services and end-to-end \nsolutions powered by the iconic Rhodotron. 01\nIndustrial \nsolutions\nThese solutions all",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "How does Ion Beam Applications SA's customer base and sales revenue compare to its competitors in the KYC and credit risk analysis industry?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA customer base size vs competitors",
                  "results": [
                    {
                      "text": "cellent sales in our businesses \n(Proton Therapy, Dosimetry, Industrial Solutions \nand RadioPharma Solutions), we are managing an \nincreasingly larger installed base and are, as a result, focusing more on service and upgrades. Patients / Clients\nShareholders\nEmployees\nSociety\nPlanet\n2\nIBA\nCORPORATE BROCHURE 2024",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "sales revenue comparison Ion Beam Applications SA vs competitors",
                  "results": [
                    {
                      "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "market share by customer segment for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "chapter_title": "Business Activities",
          "section_title": "Operations",
          "description": "Main lines of business, products/services offered, revenue streams.",
          "questions": [
            {
              "question": "What products and services does Ion Beam Applications SA primarily offer, and how do they relate to the KYC and credit risk analysis?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA product offerings",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Ion Beam Applications SA service description",
                  "results": [
                    {
                      "text": "ich will determine how the revenue is recognised. Equipment and installation services \nThe main activity of the Group consists of the construction of proton-therapy and other accelerators equipment and the \ninstallation services for its customers. Such contracts with customers are referred to as equipment and installation services, it represents the most important portion of IBAs revenue. Services \nThe Group provides operation and maintenance services which relate to the daily functioning and ma",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "KYC implications of Ion Beam Applications SA products",
                  "results": [
                    {
                      "text": "ith IBA RadioPharma Solutions and Proton Therapy. The TSC serves as an intelligent knowledge repository \nfacilitating efficient knowledge sharing, accelerating \ntroubleshooting processes, and fostering autonomy in \nproblem-solving endeavors. E-BEAM AND X-RAY IRRADIATION IS \nRECOGNIZED AS THE SAFEST TECHNOLOGY \nTO HANDLE THE GROWTH OF THE MEDICAL \nDEVICE INDUSTRY\nThe medical device industry has a wide range of products that \nenable patient diagnosis and treatment.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the main revenue streams for Ion Beam Applications SA, and how do they impact the credit risk assessment?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA revenue streams",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Ion Beam Applications SA business model analysis",
                  "results": [
                    {
                      "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Credit risk implications of Ion Beam Applications SA revenue",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What specific operational factors could influence Ion Beam Applications SA's ability to manage KYC and credit risk?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA operational risks",
                  "results": [
                    {
                      "text": "ions \ndiffer greatly from one country to another. Operational risks \nSale risk \nIn general, IBAs customers are diversified \n(public and private sector) and located on \nseveral continents. Each year the Company \ndepends on multiple orders, particularly for its \nproton therapy systems that are implemented \nover several financial years. One additional \norder or one order less, or changes in an order \nthat were not anticipated at the beginning of the \nyear, are characteristics of this field of business \nthat can have a significant impact over several \naccounting periods.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "KYC and credit risk management in Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "=== Page 118 ===\nIBA Annual Report 2023 \n115. 1. Summary of significant group accounting \npolicies \n1.1. THE REPORTING ENTITY \nIon Beam Applications SA (the Company or \nthe Parent), founded in 1986, and its \nsubsidiaries (together, the Group or IBA) are \ncommitted to technological progress in the field \nof cancer diagnosis and therapy and deliver \nefficient, dependable \nsolutions \nproviding \nunequalled precision. IBA also offers innovative \nsolutions for everyday hygiene and safety. The \nCompany \nis \na \nlimited \ncompany \nincorporated and domiciled in Belgium.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Operational challenges for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "Are there any notable partnerships, collaborations, or affiliations that could impact Ion Beam Applications SA's KYC and credit risk posture?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA partnerships analysis",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Collaborations impacting Ion Beam Applications SA KYC",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Affiliations influencing Ion Beam Applications SA credit risk",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "chapter_title": "Business Activities",
          "section_title": "Operational Risk Factors",
          "description": "Pricing, forex exposure, commodities, sector cyclicality, high-risk sectors.",
          "questions": [
            {
              "question": "What are the key pricing risk factors for Ion Beam Applications SA, and how can they be mitigated?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA pricing risk factors",
                  "results": [
                    {
                      "text": "ions \ndiffer greatly from one country to another. Operational risks \nSale risk \nIn general, IBAs customers are diversified \n(public and private sector) and located on \nseveral continents. Each year the Company \ndepends on multiple orders, particularly for its \nproton therapy systems that are implemented \nover several financial years. One additional \norder or one order less, or changes in an order \nthat were not anticipated at the beginning of the \nyear, are characteristics of this field of business \nthat can have a significant impact over several \naccounting periods.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "pricing exposure mitigation strategies for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "sector-specific pricing risks in the ion beam technology industry",
                  "results": [
                    {
                      "text": "ions \ndiffer greatly from one country to another. Operational risks \nSale risk \nIn general, IBAs customers are diversified \n(public and private sector) and located on \nseveral continents. Each year the Company \ndepends on multiple orders, particularly for its \nproton therapy systems that are implemented \nover several financial years. One additional \norder or one order less, or changes in an order \nthat were not anticipated at the beginning of the \nyear, are characteristics of this field of business \nthat can have a significant impact over several \naccounting periods.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the operational risks associated with forex exposure for Ion Beam Applications SA, and how can they be managed?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA forex exposure risks",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "foreign exchange risk management strategies for the ion beam technology sector",
                  "results": [
                    {
                      "text": "=== Page 59 ===\nIBA Annual Report 2023 \n56. IBA \ntransactions, with reporting to the Audit \nCommittee of the Group four times a year. The Group has certain investments In foreign \noperations, whose net assets are exposed to \nforeign currency translation risk. As appropriate, currency exposure arising from the net assets of \nthe Groups foreign operations may be managed \nthrough borrowings denominated in the relevant \ncurrencies. Proton Therapy segment is impacted by the \nfluctuation of the USD exchange rate against \nEUR.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "operational risks of currency fluctuations on company performance",
                  "results": [
                    {
                      "text": "from net investments in non-Eurozone \noperations. Approximately 5.0% of the Groups \nsales (4.5% in 2022) are denominated in \ncurrencies other than the functional currency of \nthe operating unit making the sales, while 97.0% \nof costs (94.0% in 2022) are denominated in the \nunits functional currency. While the functional currency of the parent \ncompany of the Group is the euro, the Groups \nexposure to foreign currencies is related \nprimarily to the US dollar, Chinese yuan, Indian \nrupee, Russian ruble and Canadian dollar.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the major commodities involved in Ion Beam Applications SA's operations, and what are the associated operational risks?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA commodity exposure risk",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "commodity-related operational risks for the ion beam technology industry",
                  "results": [
                    {
                      "text": "ions \ndiffer greatly from one country to another. Operational risks \nSale risk \nIn general, IBAs customers are diversified \n(public and private sector) and located on \nseveral continents. Each year the Company \ndepends on multiple orders, particularly for its \nproton therapy systems that are implemented \nover several financial years. One additional \norder or one order less, or changes in an order \nthat were not anticipated at the beginning of the \nyear, are characteristics of this field of business \nthat can have a significant impact over several \naccounting periods.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "sector-specific commodity price volatility risks",
                  "results": [
                    {
                      "text": "luation method (fair \nvalue and carrying amount). The carrying \namount of these financial assets represents the \nmaximum credit exposure of the Group. Foreign currency risk \nThe Group operates internationally and as such, is exposed to foreign exchange risks arising from \ncommercial transactions (sales and supply \ncontracts), from financial assets and liabilities, and from net investments in non-Eurozone \noperations.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the key sector cyclicality risks for Ion Beam Applications SA, and how can they be addressed?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA sector cyclicality risks",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "cyclical risk management strategies for the ion beam technology sector",
                  "results": [
                    {
                      "text": "assessing \nperformance of the operating segments. On the basis of its internal financial reports and given the Groups primary source \nof risk and profitability, IBA has identified two operating segments: - \nProton therapy and other accelerators: This segment constitutes the technological basis of the Groups many \nbusinesses and encompasses development, fabrication, and services associated with medical and industrial \nparticle accelerators and proton therapy systems. - \nDosimetry: This segment in",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "sector-specific economic downturn risks",
                  "results": [
                    {
                      "text": "203-2 \nSignificant indirect economic impacts \np80 AR2023 Management report / corporate governance statement / codes of \nconduct / policy and targets \np7 AR2023 Patient care, what makes our heart beat \n205-3 \nConfirmed incidents of corruptions and \nactions taken \np51 AR2023 Management report / principal risks and uncertainties faced by the \ncompany \nGRI 2016 \np45 AR2023 Management report / highlights of the year",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "chapter_title": "Business Activities",
          "section_title": "Sector",
          "description": "Detailed market segment(s) in which the company operates.",
          "questions": [
            {
              "question": "What are the primary sectors and markets in which Ion Beam Applications SA operates?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA market segments",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "industry sectors of Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "market space of Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "How does Ion Beam Applications SA's product portfolio align with the needs of its target sector?",
              "queries": [
                {
                  "query": "product offerings of Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "alignment of Ion Beam Applications SA products with industry requirements",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "market relevance of Ion Beam Applications SA products",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the key characteristics and trends in the sector where Ion Beam Applications SA operates?",
              "queries": [
                {
                  "query": "sector trends affecting Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "key drivers in the market space of Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "industry dynamics impacting Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "requiring IBA to adapt to the evolving landscape. Nevertheless, the market continues to expand \non the long term, and this situation has neither \nreduced nor slowed down the interest in E-beam \nand X-ray solutions, but rather prompted IBA \nto further develop and enhance its products offerings \nand customer service. To capture this long-term trend, IBA has developed \na new portfolio of services and end-to-end \nsolutions powered by the iconic Rhodotron. 01\nIndustrial \nsolutions\nThese solutions all",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the specific risks and challenges associated with operating in the sector where Ion Beam Applications SA operates?",
              "queries": [
                {
                  "query": "risks in the sector of Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "challenges faced by Ion Beam Applications SA in its market space",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "sector-specific risk factors for Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "ions \ndiffer greatly from one country to another. Operational risks \nSale risk \nIn general, IBAs customers are diversified \n(public and private sector) and located on \nseveral continents. Each year the Company \ndepends on multiple orders, particularly for its \nproton therapy systems that are implemented \nover several financial years. One additional \norder or one order less, or changes in an order \nthat were not anticipated at the beginning of the \nyear, are characteristics of this field of business \nthat can have a significant impact over several \naccounting periods.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "How does Ion Beam Applications SA's business model and strategy align with the needs and expectations of its target sector?",
              "queries": [
                {
                  "query": "business model of Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "strategy of Ion Beam Applications SA in its market space",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "alignment of Ion Beam Applications SA business model with industry requirements",
                  "results": [
                    {
                      "text": "=== Page 185 ===\nIBA Annual Report 2021 \n182. CORPORATE NAME \nIon Beam Applications SA, abbreviated IBA SA. Following a resolution of the Extraordinary \nGeneral Meeting of shareholders of the \nCompany held on June 14, 2023 article 1 of the \nbylaws has been amended and now reads as \nfollows: Article 1: The Company takes the form of a public limited \ncompany. The name of the Company is Ion \nBeam Applications and, in short, IBA. \" \nREGISTERED OFFICE \nChemin du Cyclotron, 3; B-1348 Louvain-la-\nNeuve",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "chapter_title": "Business Activities",
          "section_title": "Suppliers & Customers",
          "description": "Major suppliers, customer portfolio, and dependency risks.",
          "questions": [
            {
              "question": "What are the key suppliers of Ion Beam Applications SA and their respective market shares?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA major suppliers",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "suppliers in ion beam applications sa",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "market share of suppliers iba",
                  "results": [
                    {
                      "text": "=== Page 42 ===\nENGAGING WITH OUR SUPPLY CHAIN\nWe believe that a strong and responsible supply chain benefits \nour community. IBA has more than 100 main suppliers worldwide supporting \nits design and product manufacturing. The majority of IBA \nsuppliers are located in Europe. IBA suppliers have been \nselected for their ability to best comply with requirements as \nstipulated by ISO 13485:2016. The selection and qualification \nprocess of a supplier considers the criticality of the supplied \ngoods and services.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "Who are the top customers of Ion Beam Applications SA, what products or services do they purchase, and how often?",
              "queries": [
                {
                  "query": "ion beam applications sa customer portfolio",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "top customers iba",
                  "results": [
                    {
                      "text": "food irradiation \nand environmental applications. Every initiative pursued prioritizes customers \nas the focal point of its vision. In line with this \nphilosophy, IBA has established a new Customer \nSuccess team dedicated to delivering optimal \nservice and attention to its clients. Furthermore, in a bid to enhance proximity to its \nexisting customer base, IBA has bolstered its regional \npresence in the United States by quadrupling local \nresources.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "purchase frequency analysis iba",
                  "results": [
                    {
                      "text": ") are accounted for using the acquisition method. During the purchase \nprice allocation process, IBA determines the fair value of the acquirees identifiable net assets, liabilities, and contingent \nliabilities and allocates the consideration to these. The consideration transferred for the acquisition of a subsidiary is measured at fair value and includes any contingent \nconsideration. It is common to have an element of variable consideration such as an earn out which is contingent to the \nfuture performance of the acquired business.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What are the potential dependency risks associated with suppliers and customers for Ion Beam Applications SA?",
              "queries": [
                {
                  "query": "dependency risks iba suppliers",
                  "results": [
                    {
                      "text": "ve an impact \non the level of inventory required. Product development risk \nBecause IBA does not have a full product in-\nhouse testing capability, new products or",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "risks from ion beam applications sa supply chain",
                  "results": [
                    {
                      "text": "ions \ndiffer greatly from one country to another. Operational risks \nSale risk \nIn general, IBAs customers are diversified \n(public and private sector) and located on \nseveral continents. Each year the Company \ndepends on multiple orders, particularly for its \nproton therapy systems that are implemented \nover several financial years. One additional \norder or one order less, or changes in an order \nthat were not anticipated at the beginning of the \nyear, are characteristics of this field of business \nthat can have a significant impact over several \naccounting periods.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "customer concentration risk iba",
                  "results": [
                    {
                      "text": "ve an impact \non the level of inventory required. Product development risk \nBecause IBA does not have a full product in-\nhouse testing capability, new products or",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    {
      "chapter_title": "Recent Developments",
      "sections": [
        {
          "chapter_title": "Recent Developments",
          "section_title": "Recent Developments",
          "description": "Material events such as M&A, regulatory actions, new product launches.",
          "questions": [
            {
              "question": "What have been the key M&A activities for Ion Beam Applications SA in the last two years?",
              "queries": [
                {
                  "query": "Ion Beam Applications M&A history",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "recent acquisitions Ion Beam Applications",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Ion Beam Applications corporate development",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "How has the regulatory environment impacted Ion Beam Applications SA's business operations and strategy?",
              "queries": [
                {
                  "query": "regulatory actions affecting Ion Beam Applications",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "compliance issues Ion Beam Applications",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "industry regulations impacting Ion Beam Applications",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What new products or technologies has Ion Beam Applications SA introduced to the market in recent times?",
              "queries": [
                {
                  "query": "Ion Beam Applications product launches",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "new technology developments Ion Beam Applications",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "innovations ion beam applications SA",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    {
      "chapter_title": "References",
      "sections": [
        {
          "chapter_title": "References",
          "section_title": "References",
          "description": "Sources used: filings, financial reports, external data.",
          "questions": [
            {
              "question": "What financial reports and filings by Ion Beam Applications SA provide relevant information for a comprehensive KYC analysis?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA annual report",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Ion Beam Applications SA 10-K filing",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Ion Beam Applications SA investor relations website",
                  "results": [
                    {
                      "text": "company \nincorporated and domiciled in Belgium. The \naddress of its registered office is Chemin du \nCyclotron, 3; B-1348 \nLouvain-la-Neuve, Belgium. Ion Beam Applications SA is the \nmother Company of the Group and the Ultimate \nParent. The Company is listed on the pan-European \nEuronext stock exchange (B-compartment) and \nis included in the BEL Mid Index. IBA publishes condensed half-yearly and \nannual consolidated financial statements which \nhave been prepared in accordance with IFRS \nas endorsed by EU.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What external data sources can be used to supplement or verify the credit risk assessment for Ion Beam Applications SA?",
              "queries": [
                {
                  "query": "credit rating agencies Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Ion Beam Applications SA news articles and press releases",
                  "results": [
                    {
                      "text": "=== Page 185 ===\nIBA Annual Report 2021 \n182. CORPORATE NAME \nIon Beam Applications SA, abbreviated IBA SA. Following a resolution of the Extraordinary \nGeneral Meeting of shareholders of the \nCompany held on June 14, 2023 article 1 of the \nbylaws has been amended and now reads as \nfollows: Article 1: The Company takes the form of a public limited \ncompany. The name of the Company is Ion \nBeam Applications and, in short, IBA. \" \nREGISTERED OFFICE \nChemin du Cyclotron, 3; B-1348 Louvain-la-\nNeuve",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "external auditors' reports on Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "Are there any specific regulations or industry standards that need to be considered in the KYC analysis for Ion Beam Applications SA?",
              "queries": [
                {
                  "query": "KYC requirements EU financial institutions",
                  "results": [
                    {
                      "text": "sh flows for the year then ended, in accordance with International Financial \nReporting Standards as adopted by the European Union and with the legal and regulatory \nrequirements applicable in Belgium. Basis for unqualified opinion",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Ion Beam Applications SA compliance with AML regulations",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "industry standards for credit risk assessment",
                  "results": [
                    {
                      "text": "ose \ncooperation with the Groups operating units. Credit risk \nThe Group has exposure to credit risk. In order \nto cover this risk, the Company policy for \nequipment contracts is to have confirmed letters \nof credit issued by its customers prior to \nshipment of the equipment, or to contract a \nspecific credit insurance from either the Belgian \nofficial export credit agency Credendo or private \ninsurers. Besides, the consolidated financial statements \npresents the financial assets and the financial \nliabilities of the Group by valuation method (fair \nvalue and carrying amount).",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            },
            {
              "question": "What additional sources of information are available to provide context and supporting evidence for the comprehensive KYC analysis?",
              "queries": [
                {
                  "query": "Ion Beam Applications SA Wikipedia page",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "Ion Beam Applications SA social media presence",
                  "results": [
                    {
                      "text": "00% \n100% \nIon Beam Beijing Applications Co. Ltd. Beijing, China \n100% \n100% \nIBA RadioIsotopes France SAS \nLyon, France \n100% \n100% \nIBA Dosimetry Ltd. Schwarzenbruck, Germany \n100% \n100% \nIBA Dosimetry America Inc. Bartlett, USA \n100% \n100% \nIBA Proton Therapy Inc. Edgewood New York, USA \n100% \n100% \nIBA Industrial Inc. Edgewood New York, USA \n100% \n100% \nIBA USA Inc. Edgewood New York, USA \n100% \n100% \nIBA Particle Therapy Ltd.",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                },
                {
                  "query": "analyst reports on Ion Beam Applications SA",
                  "results": [
                    {
                      "text": "The consolidated accounts of Ion Beam Application SA for the fiscal year ended on December 31, 2022, have been audited by another auditor who expressed an unqualified opinion on these \nconsolidated accounts in their report dated April 28, 2023. Responsibilities of the board of directors for the preparation of the consolidated accounts",
                      "source": "",
                      "score": 0.0
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    }
  ]
}